Merck: clinical trial collaboration deal with Novocure
(CercleFinance.com) - Novocure said that it has entered into a clinical trial collaboration deal with Merck to develop its electric field cancer therapy together with blockbuster Keytruda for the treatment of non-small cell lung cancer.
The US oncology firm said that the companies plan to conduct a phase 2 pilot study for the first-line treatment of intrathoracic advanced or metastatic, PD-L1 positive non-small cell lung cancer.
The study is designed to enroll approximately 66 patients in the US and is expected to begin in the second half of 2020.
Novocure's cancer therapy uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing cancer cells to die.
Copyright (c) 2020 CercleFinance.com. All rights reserved.